1. Scrip
  2. >>Business

Dr Reddy’s CEO On Payer Dynamics, China Commitment And Disruption

 
• By Anju Ghangurde

Dr Reddy’s CEO tells Scrip in an interview that it isn’t business as usual, in general, in the US, where it is refining its proprietary products strategy to focus on ‘bigger assets’ in the backdrop of the payer environment there. The Indian company is, however, upbeat on plans for China.

GV Prasad
DR REDDY'S CEO G V PRASAD

Dr. Reddy's Laboratories Ltd. (DRL) continues to chisel and recalibrate its operations in the backdrop of a tough business environment in key markets like the US, but the Indian firm also expects to put the pedal to the metal in China, a market where it has had a long-standing base.(Also see "Big Cost Cuts At Dr Reddy’s, US Big Ticket Launch Progress Is Key" - Scrip, 27 July, 2018.)(Also see "India Pharma Firms Eye China, Dr Reddy’s Sees ‘Great Opportunity’ There" - Scrip, 29 October, 2018.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

 
• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.

Korean Biotech Roundup: GNT Set For First Direct Korean Biopharma IPO On Nasdaq

 
• By Jung Won Shin

GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.

Ironwood To Consider All Options With Apraglutide Setback In SBS

 
• By Joseph Haas

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

More from Scrip

Ironwood To Consider All Options With Apraglutide Setback In SBS

 
• By Joseph Haas

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 
• By Andrew McConaghie

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.